MED28

Across TCGA pan-cancer cohorts, MED28 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated MED28 data layer compared with 5 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MED28 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MED28 expression acts as an unfavorable survival marker, although some lineages such as UCS and BRCA show a favorable association.

UCS, LIHC, and BRCA are the cancer types where MED28 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	III,IV	0.559	0.189	.004	86	view →
LIHC	DFS	Quartile	All	0.275	0.580	.002	66	view →
BRCA	OS	Median	III,IV	0.954	0.846	<.001	52	view →
KIRC	OS	Median	All	0.849	0.762	.003	37	view →
ESCA	DFS	Median	IV	0.205	0.634	.006	27	view →
CESC	DFS	Quartile	III,IV	0.142	0.745	.002	24	view →
LUAD	DFS	Tertile	III,IV	0.777	0.501	.017	24	view →
SKCM	DFS	Quartile	All	0.798	0.635	.002	21	view →
GBM	DFS	Tertile	All	0.442	0.175	.004	18	view →
HNSC	OS	Quartile	All	0.630	0.859	.002	15	view →
UVM	DFS	Quartile	III,IV	0.283	0.856	.013	15	view →
ACC	DFS	Tertile	All	0.250	0.684	.008	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

MED28–UCS (OS)

Open the UCS breakdown →